Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.51 |
| ▸ | ESRRA | P11474 | 3/20 | 0.46 |
| ▸ | AR | P10275 | 7/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14661906 | 0.88 | SLC22A12 (0.48) | SLC22A12ESRRAARTTREPAS1 | |
| SCHEMBL14656177 | 0.88 | SLC22A12 (0.48) | SLC22A12ESRRAARTTREPAS1 | |
| SCHEMBL14656239 | 0.87 | SLC22A12 (0.47) | SLC22A12ESRRAARTTR | |
| SCHEMBL14656131 | 0.85 | SLC22A12 (0.51) | SLC22A12ESRRAARHTR2ASLC6A4 | |
| SCHEMBL9889474 | 0.85 | PLA2G7 (0.51) | SLC22A12ESRRAARTTRHTR2A | |
| SCHEMBL17302908 | 0.82 | SLC22A12 (0.40) | SLC22A12ESRRAAREPAS1 | |
| SCHEMBL875640 | 0.82 | AR (0.57) | SLC22A12ESRRAAR | |
| SCHEMBL14656413 | 0.82 | SLC22A12 (0.48) | SLC22A12ARTTREPAS1 | |
| SCHEMBL14656186 | 0.82 | SLC22A12 (0.51) | SLC22A12ESRRAARHTR2ASLC6A4 | |
| SCHEMBL14662061 | 0.82 | AR (0.44) | SLC22A12ESRRAARTTREPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8637536-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-01-28 | — | — | US | disclosed |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142717-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | SLC22A12 1907/4885ESRRA 3666/4885AR 4068/4885 |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | SLC22A12 2438/4885ESRRA 3825/4885AR 3287/4885 |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | SLC22A12 2505/4885ESRRA 3737/4885AR 3324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.